Summary: The dose-limiting toxicity for vincristine is peripheral neuropathy which can be potentiated with concurrent usage of azole antifungals. The current retrospective study assessed the incidence of concurrent vincristine and azole antifungal usage to determine if it led to increased neurotoxicity for the Kaiser Northern California pediatric acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma patient population. Data were obtained from the electronic medical record (2007 to 2014). In total, 130 subjects received at least one dose of vincristine for ALL or Hodgkin lymphoma (median age 9, 88% ALL, 58% male, 47% Caucasian). Thirty one percent of patients received concurrent antifungal usage (fluconazole, 78%; voriconazole, 10%; fluconazole/voriconazole, 12%); however, concurrent antifungal usage accounted for <15% of vincristine doses. Grade 2 or greater neuropathy occurred in 51% of patients; grade 3 neuropathy was present in 8% of patients. No difference in the incidence of grade 2 or greater neuropathy was observed with the concurrent use of antifungal therapy (P = 0.35), sex (P = 0.59), type of cancer (P = 0.41), ethnicity (P = 0.29), or age (P = 0.39), but was higher with increasing amount of vincristine doses (P = 0.004). These results suggest that concurrent azole antifungal usage with vincristine for patients with ALL and Hodgkin lymphoma was low in the Kaiser Northern California population and limited usage as needed may be reasonable and safe.
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Key Words: vincristine, neuropathy, azole antifungal, ALL, Hodgkin lymphoma (J Pediatr Hematol Oncol 2018;40:e273-e277) V incristine is an antineoplastic agent used for treatment of many cancers including acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma. It prevents chromosome separation in metaphase by binding to tubulin, ultimately leading to cell death. The dose-limiting toxicity is peripheral neuropathy 1 with metabolism occurring predominantly through CYP3A4 and CYP3A5. 2 Leukemia and lymphoma patients are at risk for fungal infections and many are treated with azole antifungals while receiving doses of vincristine. Despite the increased risk of infection, there is currently insufficient evidence to make guidelines with regard to prophylaxis for pediatric patients with ALL or Hodgkin lymphoma; however certain populations may be at higher risk for fungal infections and receive prophylactic azole antifungals concurrently with vincristine. 3, 4 The azole antifungals have the potential to increase drug levels through CYP3A4 inhibition and inhibition of P-glycoprotein mediated vincristine efflux, 5 thus there is concern for increased toxicity with concurrent usage. Prior studies have indicated that there is increased vincristine toxicity with prophylactic antifungal usage 6,7 while others have not found this effect. 8 It is still unclear how often concurrent usage occurs and whether limited duration concurrent usage would lead to increased toxicity.
The Kaiser Permanente Northern California health care system represents 4 million patients with an electronic medical record dating back to 2007. Patients with Kaiser Foundation health insurance receive all of their medical care in a single system of hospitals, clinics, and pharmacies. A comprehensive description of antifungal and vincristine usage over the course of therapy can thus be obtained from review of these medical records.
The current retrospective study aimed to determine the incidence of concurrent vincristine and azole antifungal use and if this drug combination led to increased neurotoxicity in ALL and Hodgkin lymphoma for the Kaiser Northern California pediatric patient population. It assessed the effects of demographics and cumulative vincristine exposure on neurotoxicity.
MATERIALS AND METHODS

Patient Population and Data Extraction
The retrospective cohort comprised patients below 22 years of age who were treated in the Kaiser Permanente Northern California medical system. Patients were identified as those who had received vincristine and had a diagnosis of ALL or Hodgkin lymphoma from the start of the electronic medical record system (January 2007) to the date of the data pull (February 2016). Dates of all vincristine inpatient and outpatient drug administrations were extracted electronically. All azole antifungal (fluconazole, voriconazole, posaconazole, and itraconazole) inpatient drug administrations and outpatient prescriptions were pulled electronically. Demographic information including age, ethnicity (self-reported), and sex were also electronically extracted. Drug administrations of commonly used strong CYP3A4 inhibitors (ritonavir) and inducers (carbamazepine, phenytoin, phenobarbital, and oxycarbazepine) were also electronically extracted. Neuropathy information was determined through chart review of oncology notes.
Data Analysis
Concurrent Antifungal Usage
Patients who had received concurrent vincristine and antifungal usage were identified. To ensure that patients were receiving vincristine and azole antifungal concurrently, a minimum degree of overlap between administrations was defined ( Fig. 1) . Given the median half-life of 85 hours (range, 19 to 155 h) for vincristine, 9 patients who received a dose of antifungal within 7 days after the vincristine dose were considered to have concurrent usage. Patients had to receive fluconazole, posaconazole, or itraconazole ≤ 4 days before administration of vincristine given the~30-hour halflife of the drugs. [10] [11] [12] For voriconazole, the vincristine usage had to be within 1 day, given the reported 6-hour half-life of the drug. 13 Patients with overlap of antifungal and vincristine dosage at least once during treatment were considered to have concurrent usage. Those with outpatient antifungal prescriptions were assumed to be taking the antifungal for the total amount of days that the drug was prescribed.
Identification of Neuropathy
All oncology notes from the start of vincristine administration to 30 days after the final administration were reviewed to assess for the presence of neuropathy. Neuropathy was scored using the eastern cooperative oncology group (ECOG) scale (Table 1 ). 14 If multiple mentions of neuropathy occurred, then the highest grade was used for the analysis. Patients with preexisting neuropathy were excluded from the analysis.
Statistics
Fischer exacts tests were used to compare the presence or absence of grade 2 or greater neuropathy to categorical variables (antifungal use, ethnicity, sex, disease) to the incidence of grade 2 or greater neuropathy. The Wilcoxin rank sum test was used to compare the presence of grade 2 or greater neuropathy to continuous variables (age, vincristine doses).
RESULTS
In total, 130 patients receiving vincristine for ALL or Hodgkin lymphoma were identified from the electronic medical record. An additional 8 patients receiving vincristine had preexisting neuropathy and were excluded from the analysis. The median age was 9 years (range, <1 to 21 y). In total, 75 (58%) patients were male individuals and 55 (42%) were female individuals. In total, 47% were Caucasian with 4% African American, 18.5% Asian, 28.5% Hispanic, and 2% American Indian. The majority of patients were treated for ALL (88%). There were a total of 3475 vincristine doses administered with a median of 24 per patient (range, 1 to 72). In total, 41 patients (31%) received concurrent antifungal usage (fluconazole, 32; voriconazole, 4; and fluconazole/ voriconazole, 5) ( Fig. 2A) . Median number of times of antifungal overlap per patient was 2 (range, 1 to 14) and occurred in 12% of vincristine doses. Only one patient in the study received a CYP3A4 inducer (phenytoin) concurrently with vincristine administration. This patient was included in the analysis since the grade 2 neuropathy developed after 14 vincristine doses, but before concurrent phenytoin usage. Neuropathy (grade 2 or higher) was documented in 66 patients (51%) with 10 patients (8%) having grade 3 neuropathy. The majority of documented neuropathy involved the absence of deep tendon reflexes (~75%) without additional information with regard to other motor or sensory neuropathy. After initial documentation of neuropathy, it was confirmed in a second note in 74% of subjects, and in at least 2 additional notes in 42% of subjects. Given the low incidence of grade 3 or greater neuropathy, statistical comparisons were limited to grade 2 or greater neuropathy (Table 2) . No difference in the incidence of grade 2 or greater neuropathy was observed with the concurrent use of antifungal therapy ( Fig. 2B , P = 0.35). No difference in the incidence of grade 2 or greater neuropathy was observed with the concurrent use of voriconazole versus fluconazole or no azole usage (P = 0.49). The time to develop grade 2 neuropathy was also not different with the use of antifungal (Fig. 3) . Grade 3 neuropathy developed later than grade 2. No differences in the presence of grade 2 or greater neuropathy were observed for sex (P = 0.59), disease status (ALL vs. Hodgkin lymphoma; P = 0.41), ethnicity (P = 0.29), African American versus other ethnicities (P = 0.37), or age (P = 0.39). The number of vincristine doses was strongly related to the incidence of grade 2 or greater neuropathy ( Fig. 4 , P = 0.004). The amount of antifungal overlap per patient was derived from outpatient azole prescriptions in 25 of 41 patients in the antifungal group. As 85% of patients received at least one course of inpatient with or without outpatient antifungal, we believe that the comparison between the presence of any concurrent antifungal usage and neuropathy is valid; however, the data were not felt to be granular enough to compare the total amount of overlap to the occurrence of neuropathy. There were 10 patients with grade 3 neuropathy and 6 of 10 experienced severe weakness. Five of the 10 patients had concurrent antifungal usage. Total vincristine doses ranged from 14 to 49 (median, 27) in patients without antifungal overlap and from 14 to 32 (median, 22) in patients with antifungal overlap. There were 5 AfricanAmerican patients in the study and 4 of these patients had 
DISCUSSION
Leukemia and lymphoma patients can develop invasive fungal infections over the course of treatment which may require azole antifungal administration. Vincristine is a commonly used drug in leukemia and lymphoma regimens. Vincristine-induced peripheral neuropathy involves both sensory and motor functions. The mechanism of action of vincristine is binding to β-tubulin which prevents cell division and leads to cell death. The disruption of the β-tubulin assembly and disassembly leads to swelling and ultimately damage of myelinated and unmyelinated nerve fibers. 1, 15 Therefore, the incidence and severity of symptoms would be expected to be related to the duration and dose received by patients. As azole antifungals are CYP3A4 inhibitors and vincristine is a CYP3A4 substrate, concurrent antifungal usage places patients at risk of worsening dose-limiting peripheral neuropathy and compromising the administration of full dose curative therapies. The current study aimed to characterize concurrent antifungal usage patterns in patients with ALL and Hodgkin lymphoma patients and determine if it increased the incidence of higher grade ( ≥ 2) peripheral neuropathy.
Overall concurrent antifungal usage accounted for 12% of the total vincristine doses in a patients, thus the frequency of concurrent usage was small. No differences were seen between incidence of grade 2 or greater neuropathy and antifungal usage. No differences in grade 2 or greater neuropathy were present based on age, ethnicity, disease status, or sex. The number of vincristine doses was higher in patients with neuropathy.
There were more patients with concurrent antifungal usage in the grade 3 neuropathy group (50% as compared with 30%). However, due to the low incidence of reported grade 3 neuropathy the study was underpowered to find a difference. African-American patients were few in the study and did not have grade 3 neuropathy. Prior studies suggested that that the higher expression of CYP3A5 allows these patients to metabolize the drug better leading to decreased toxicity albeit with decreased efficacy due to lower vincristine drug levels. 16 Although the current study was retrospective, Kaiser Northern California is a closed system with patients receiving all of their care, chemotherapy, and prescriptions within the same network of hospitals, thus the information in the electronic medical record represents a complete medication record. However, determining concurrent usage of antifungal and vincristine administration was still challenging for patients receiving outpatient antifungals, as this was based on prescriptions. Information regarding whether the patient filled the prescription, if the medication was started, and if the medication was held was lacking in the electronic data extraction and chart review. As 85% of patients had at least one course of inpatient with or without outpatient antifungal, we believe that the comparison between concurrent antifungal usage and neuropathy is valid. However, we do not have the granularity in these data to compare amount of concurrent usage to the occurrence of neuropathy.
There have been several studies looking at vincristineassociated toxicity with concurrent antifungal usage. Moriyama et al 17 investigated at the incidence of adverse drug reactions with vincristine and azole antifungals through literature review and found the most common adverse drug reactions in pediatrics were: gastrointestinal (86%), electrolyte abnormalities (62%), autonomic neuropathy (62%), and peripheral neuropathy (48%). Van Schie et al 6 studied 20 pediatric ALL patients to compare the incidence of vincristine toxicity in the presence and absence of azole antifungal prophylaxis and found that constipation and peripheral neuropathy were significantly increased. The majority of patients received itraconazole prophylaxis which may provide increased toxicity due to potential inhibition of P-glycoprotein in addition to CYP3A4, as compared with the current study where patients received fluconazole or voriconazole. Teusink et al 7 found that fluconazole prophylaxis during induction chemotherapy for pediatric ALL patients resulted in a significant increase in the incidence of neuropathy, but no differences in gastrointestinal toxicity. In contrast, Smitherman et al 8 studied fluconazole prophylaxis during induction therapy for pediatric ALL patients and did not find an increased risk of vincristine-related toxicity. There was an increased risk of vincristine toxicity in patients 10 years and older which was independent of fluconazole usage.
Between study comparisons of neuropathy is complicated by variability in scoring systems. The current study used the ECOG scoring system, finding a 51% rate of grade 2 or greater neuropathy and 8% rate of grade 3 or higher neuropathy. This is a higher rate of neuropathy than was seen in a prior prospective study of pediatric ALL patients, which found 27% grades 2 to 4 neuropathy, with 11% grade 3 or greater neuropathy using the common terminology criteria for adverse events scoring system. 18 A separate prospective pediatric ALL patients study using the TNS scoring system found 78% of children had vincristineinduced peripheral neuropathy of any grade and in these patients common terminology criteria for adverse eventsderived grades 1, 2, 3, and 4 sensory neuropathy occurred in 31%, 3%, 2%, and 0%, and motor neuropathy in 18%, 4%, 2%, and 0% of children, respectively. 19 As the current study was retrospective and the majority (~75%) of the documented neuropathy was related to the presence of absence of deep tendon reflexes without other details on sensory or motor neuropathy, the authors used the ECOG scoring system to best capture the neuropathy information available in the electronic medical record. A prior study found higher rates of chemotherapy-induced peripheral neuropathy with prospective evaluations as compared with a retrospective evaluation of the electronic medical record. 20 Although we found higher rates of neuropathy than other prior prospective pediatric studies, this remains limitation of the current retrospective study. Prospective collection of data would likely have yielded higher rates of neuropathy and more granularity on the types of neuropathy.
Patients who received antifungal administration within 7 days of the vincristine dose were considered to have concurrent usage in order to capture all possible concomitant usage. However, the majority of vincristine may be metabolized within the first 24 hours. Using a more stringent cut-off of one day for antifungal administration after vincristine dose and the same criteria for antifungal usage before vincristine dose resulted in 6 fewer patients with concurrent antifungal usage, but still did not yield a significant difference in the incidence of grade 2 or greater neuropathy with the concurrent use of antifungal therapy (P = 0.32). Patients with concurrent usage received almost exclusively fluconazole (78%) which is considered a weaker Cytochrome P450 inhibitor than voriconazole, posaconazole, or itraconazole, thus a difference in the frequency of neuropathy may have been found in a patient population receiving more potent antifungals. Although the vincristine (mg/m 2 ) per dose may also relate to toxicity, this information was incompletely extracted from the database thus could not be evaluated in the current study.
The study cannot make conclusions about prolonged usage of azole antifungal as prophylaxis or treatment in the setting of multiple vincristine doses. However, overall the current results suggest that concurrent azole antifungal usage with vincristine for pediatric patients with ALL and Hodgkin lymphoma patients was low in the Kaiser Northern California population and this limited usage as needed may be reasonable and safe.
